Menu
1 min read · estimated
APPROVED USE
What FDA approved
Adults with relapsed or refractory follicular lymphoma after at least three systemic treatment lines. FDA records list withdrawal of this indication on May 31, 2022.
LAMPGEN ANALYSIS
Why it matters
The follicular lymphoma authorization used a different prior-treatment threshold from the same-day marginal zone lymphoma action.
What research teams should watch
Keep the histology and three-line threshold in the record so separate lymphoma populations can be analyzed.
PRIMARY RECORDS